Ibuprofen/Caffeine Lower Back or Neck Pain Study

Neck Pain Clinical Trial

Official title:

A Randomized, Placebo- and Active-controlled Multi-country, Multi-centre Parallel Group Study to Evaluate the Efficacy and Safety of a Fixed Dose Combination of 400 mg Ibuprofen and 100 mg Caffeine Compared to Ibuprofen 400 mg and Placebo in Patients With Acute Lower Back or Neck Pain.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03003000
• Other study ID #: 1335.5
• Secondary ID: 2016-000902-12
• Status: Completed
• Phase: Phase 3
• Start date: December 20, 2016
• Est. completion date: September 28, 2017

Study information

• Verified date: March 2019
• Source: Boehringer Ingelheim
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To assess the efficacy and safety of a 400 mg ibuprofen/100 mg caffeine tablet in comparison to a 400 mg ibuprofen tablet for the treatment of acute lower back or neck pain. To assess the safety and tolerability of a 400 mg ibuprofen/100 mg caffeine tablet in comparison to a 400 mg ibuprofen tablet and a placebo tablet.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 635
• Est. completion date: September 28, 2017
• Est. primary completion date: September 24, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Signed and dated written informed consent at Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation.

• Male or female patients who are >=18 years with current diagnosis of acute back pain or of neck pain for at least 24 hours, but less than 21 days.

• Acute back pain or acute neck pain resulting in Pain on Movement (POM) >=5 on the 0-10 Numerical Rating Scale (NRS) for at least one POM procedure out of 5 standardised procedures.

• Sensitivity to algometric pressure on the painful trigger point <= 25 N/cm².

• Women of childbearing potential must be ready and able to use highly effective methods of birth control.

• Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaires.

• Examined by the attending physician and medically cleared to participate in the study

• In good general health, with a body mass index (BMI) < 30, and have no contraindications to any of the study medication

Exclusion criteria:

• History of 3 or more episodes of back or neck pain in the last 6 months excluding the current episode.

• Patients with pain at rest >= 9

• Patient with chronic back or neck pain as defined as pain for 3 weeks or longer.

• Back or neck pain that is attributable to any identifiable cause (eg. disc prolapse, spondylolisthesis, osteomalacia, inflammatory arthritis, metabolic, neurological diseases or tumour)

• Any strains of the back or neck muscles documented by clinical evaluation and anamnesis that occurred 21 days to 3 months prior to the screening visit.

• Surgery due to back or neck pain or rehabilitation due to back or neck pain in the last 12 months.

• Prior use within the last 3 days before Visit 1 or concomitant use of any anti- inflammatory drugs, heparinoids, muscle relaxants or analgesics (including but not limited to short-acting glucocorticoids, non-steroidal anti-inflammatory drugs [NSAIDs], herbal preparations) for the same indication or other indications.

• Spinal injections should have been discontinued in due time (investigator's judgment) before patient enrollment to allow complete wash-out of the active ingredient based on investigator's judgment.

• Known severe hepatocellular insufficiency, severe renal insufficiency or Gilbert's syndrome (Morbus Meulengracht)

• Patients taking Central Nervous System (CNS) or other psychotropic drugs, or any nutritional supplement known to have psychotropic effects such as St. John's Wort, Chapparal, Comfrey, Germander, Gin Bu Huan, Kava, Pennyroyal Skullcap, or Valerian within two months of taking the first dose of study medication. Patients who have been on stable doses of these medications for at least two months will be allowed into the study, as long as they maintain this dose throughout the study, and their condition is judged stable by the Principal Investigator

• Any other medical condition that would interfere with efficacy and safety assessments based on investigator's judgment or any on-going clinical condition that would jeopardize patient's or site personnel's safety or study compliance based on investigator judgment

• Further exclusion criteria apply

Related Conditions & MeSH terms

• Back Pain
• Neck Pain

Intervention

Drug:
• ibuprofen

• caffeine

• placebo

Locations

Country	Name	City	State
Germany	Praxis Dr. Schaefer, 45355 Essen	Essen
Germany	Praxis Dr. Steinebach, Essen	Essen
Germany	Studienzentrum Bocholderstraße	Essen
Germany	Unterfrintroper Hausarztzentrum	Essen
Germany	Praxis Dr. Pabst, Gilching	Gilching
Germany	Praxis Kai Gastl	Gilching
Germany	medicoKIT GmbH	Goch
Germany	Clinical Research Dr. Martz	Hamburg
Germany	Praxis Dr. Dahmen, 22415 Hamburg	Hamburg
Germany	Praxis Dr. Chevts, 76199 Karlsruhe	Karlsruhe
Germany	Dünnwaldpraxis, Köln	Köln
Germany	Praxis Dr. Klein, Künzing	Künzing
Germany	Anästhesiologie Rheinbach	Rheinbach
Germany	Praxis Dr. Sauter	Wangen
Germany	Neurologie und Psychiatrie / Psychotherapie	Westerstede
Russian Federation	City Outpatient dep.no.107;clinc.pharmacology,st.petersburg	St. Petersburg
Russian Federation	Medical Centre "Reavita Med SPb" LLC	St. Petersburg
Russian Federation	State Healthcare Institution, City Out-Patient's Clinic #109	St. Petersburg

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

Germany,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Pain on Movement (POM) With Regard to the Worst Procedure (WP) Between Baseline and Day 2 (Morning, 2 Hours After Drug Intake)	The change in pain on movement (POM) with regard to the worst procedure (WP), i.e. the procedure with the highest pain score at baseline (POMwp), between baseline (morning of Day 1, pre-dosing) and Day 2 (morning, 2 hour (h) after drug intake).; POM was assessed by the patient at the performance of one standardized, muscle group specific movement and was measured by a numerical rating scale ranging from 0 = 'no pain'to 10 = 'worst pain possible for this condition'.; The procedure resulting in highest POM at baseline (worst procedure, POMWP) was repeated for an individual patient. If 2 or more procedures gave the same highest POM, the patient was asked which of the procedures giving the highest POM scores he/she considered the most unpleasant.; Change in POMwp was calculated as baseline POMwp - POMwp at Day 2 - indicating a reduction in POMwp, where the result is positive.	Baseline and Day 2
Secondary	The Area Under the Curve (AUC) for Pain on Movement (POM) With Regard to the Worst Procedure (POMwp) Between Baseline and Day 4 (Morning) (POMwpAUC72hour (h))	This is a key secondary endpoint. The area under the curve (AUC) for pain on movement (POM) with regard to the worst procedure (POMwp) between baseline and Day 4 (morning), (POMwpAUC72h ). POM was assessed by the patient at the performance of one standardized, muscle group specific movement and was measured by a numerical rating scale ranging from 0 = 'no pain'to 10 = 'worst pain possible for this condition'. A higher AUC value indicates higher POMwp	Baseline, Day 1, Day 2 and Day 4 (morning)
Secondary	The Area Under the Curve (AUC) for the Procedure With the Highest Pain Score at Baseline (POMWP) Between Baseline and Day 6 (Morning) (POM(WP)AUC(120h))	This is a key secondary endpoint. The area under the curve for pain on movement with regard to the worst procedure between baseline and Day 6 (morning) (POM(WP)AUC(120h).; POM was assessed by the patient at the performance of one standardized, muscle group specific movement and was measured by a numerical rating scale ranging from 0 = 'no pain'to 10 = 'worst pain possible for this condition'. A higher AUC value indicates higher POMwp.	Baseline, Day 1, Day 2, Day 4 and Day 6 (morning)
Secondary	Change in Pressure Algometry Between Baseline and Day 2 (Morning, 2 Hour After Drug Intake)	Change in pressure algometry between baseline and Day 2 (morning, 2 h after drug intake).; Pressure algometry was determined by the investigator as the pressure value (N/cm2) at a defined trigger point which is located in the area of POMWP. The measurement was performed by using a Somedic Algometer (Somedic AB, Sweden) or an equivalent calibrated and certified device. The pain reaction was determined by placing the algometer on the trigger point, i.e. an area of 1 cm² for which the patient indicated most painful tenderness. The pressure was constantly increased until the patient asked not to increase the pressure anymore. Upon this pain reaction, the corresponding pressure value was documented in the Electronic case report form (eCRF). The trigger point was to be marked with a ball pen to be able to repeat the subsequent assessment at the same position. Change in pressure was calculated as baseline pressure - pressure at Day 2, with a negative result indicating an improvement.	Baseline and Day 2 (morning, 2 h after drug intake)
Secondary	Global Assessment of Efficacy by the Patient at the End of Treatment (Morning of Day 6)	Global assessment of efficacy by the patient at the end of treatment (morning of Day 6) is presented. The patient/investigator assessed the overall efficacy of the trial treatment on a 4-point verbal rating scale by answering the question: "How would you rate the overall effect of the trial medication for relieving back or neck pain?" (0 = poor; 1 = fair; 2 = good; 3 = very good).	At the end of treatment (morning of Day 6)
Secondary	Number of Patients With a Decrease in POMwp of at Least 30% or 50% Between Baseline and Day 2 (Morning, 2 h After Drug Intake)	Number of patients with a decrease in POMwp of at least 30% or 50% between baseline and Day 2 (morning, 2 h after drug intake.	Baseline and Day 2 (morning, 2 h after drug intake)
Secondary	Time to First Meaningful POMwp Relief Within 2 h After the First Dose of Trial Medication	Time to event analysis of patients with first meaningful POMwp relief within 2 h after the first dose of trial medication. The percentage of observed patients with a meaningful POMwp relief within 2 h after the first dose of trial medication was reported. The procedure which resulted in the highest POM at baseline (POMwp) was repeated by the investigator 10, 20, 30, 60 and 120 min after the first dose of trial medication. The POMwp relief score (POMwpRS) was assessed by the patient at each of these time points by using a 5-point verbal rating scale (0 = no POMwp relief; 1 = little or perceptible POMwp relief; 2 = meaningful POMwp relief; 3 = a lot of POMwp relief; 4 = complete POMwp relief).; The time to first meaningful POMWP relief was the earliest assessment time point after the first application of the trial medication at which the patient reported a score of =2.	Within 2 h after the first dose of trial medication

External Links

•   Link